Ingredients & Science
DR3 Antibody Candidate SL-325 Reports Phase 1 Safety Data
The Austin-based biotech's lead candidate targets the DR3 pathway — a mechanism drawing growing interest in immune-medi…
The Austin-based biotech's lead candidate targets the DR3 pathway — a mechanism drawing growing interest in immune-medi…